Collection of Peripheral Blood Mononuclear Cells From Healthy Subjects
NCT ID: NCT05560217
Last Updated: 2022-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2022-10-10
2025-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cell Therapy in Chronic Limb Ischemia
NCT00533104
Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)
NCT01307371
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19
NCT04252118
Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia
NCT01937416
Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation
NCT02594345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood pressure:
12.0Kpa(90mmHg)≤systolic pressure\<18.7Kpa(140mmHg) 8.0Kpa(60mmHg)≤diastolic pressure\<12.0Kpa(90mmHg); Pulse rate: 60 beats/ min \~ 100 beats/ min, the athlete with high-level stamina≥50 beats/ min, normal and tidy rhythm.
Body temperature:36.3-37.2℃; Generally in good condition: no impairment of major organs, including heart, lung, liver, and kidney, no serious or uncontrolled infections, and no history of severe mental illness;
The clinical lab tests must meet the following standards:
Blood routine, blood biochemistry, normal or abnormal liver and kidney function have no clinical significance; Normal testing of coagulation function; Negative for antibody to Hepatitis A Virus (HAV-IgM); Negative for Hepatitis B Virus Surface Antigen (HBsAg); Negative for antibody to Hepatitis C Virus (HCV); Negative for antibody to Human Immunodeficiency Virus (HIV-1 and HIV-2); Negative for Syphilis; Negative for DNA to Epstein-Barr Virus (EBV). Negative for DNA to cytomegalovirus (CMV) . Negative for DNA to B19. Negative for Human T Lymphocytic leukemia Virus (HTLV).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight: male≥50kg, female≥45kg, and 18.5kg/m2≤BMI≤30kg/m2 (BMI =weight(kg)÷height(m)2);
* Blood pressure:
12.0Kpa(90mmHg)≤systolic pressure\<18.7Kpa(140mmHg) 8.0Kpa(60mmHg)≤diastolic pressure\<12.0Kpa(90mmHg); Pulse rate: 60 beats/ min \~ 100 beats/ min, the athlete with high-level stamina≥50 beats/ min, normal and tidy rhythm.
* Body temperature:36.3-37.2℃;
* Generally in good condition: no impairment of major organs, including heart, lung, liver, and kidney, no serious or uncontrolled infections, and no history of severe mental illness;
* The clinical lab tests must meet the following standards:
Blood routine, blood biochemistry, normal or abnormal liver and kidney function have no clinical significance; Normal testing of coagulation function; Negative for antibody to Hepatitis A Virus (HAV-IgM); Negative for Hepatitis B Virus Surface Antigen (HBsAg); Negative for antibody to Hepatitis C Virus (HCV); Negative for antibody to Human Immunodeficiency Virus (HIV-1 and HIV-2); Negative for Syphilis; Negative for DNA to Epstein-Barr Virus (EBV). Negative for DNA to cytomegalovirus (CMV) . Negative for DNA to B19. Negative for Human T Lymphocytic leukemia Virus (HTLV).
Exclusion Criteria
* You have neurological diseases, mental diseases, Creutzfeldt-Jakob disease and have a family medical history or those who have received treatment with tissues or tissue derivatives that may be infected by Creutzfeldt-Jakob pathogen;
* You have chronic skin diseases, especially infectious, allergic or inflammatory systemic skin diseases;
* You have allergic diseases or frequent relapse;
* You have/had malignant tumors or benign tumors cause health problems;
* You have an infectious disease, a carrier of an infectious disease, a suspected infectious disease;
* You have allogeneic tissue organ graft recipients.
* You have undergone the removal of important internal organs such as the stomach, kidneys, spleen, lungs and so on;
* Those who have caused the recipient to have infectious diseases related to blood transfusion.
* You have had minor surgery within 3 months, including appendectomy, eye surgery, etc.; major surgery within 1 year, such as: surgical treatment of gynecological benign tumor, superficial benign tumor, etc.;
* Women in pregnancy or had a miscarriage within 6 months, or post partum and in lactation within 1 year;
* Recovered from Upper respiratory tract infection no longer than one week, or from pneumonia no longer than three months;
* Recovered from Acute pyelonephritis no longer than 3 months, or within the attack period of the urinary tract stones;
* Injuries caused by or wounds contaminated by devices/apparatuses contaminated by blood or tissue fluid or tattooed within one year;
* You have received whole blood and blood component transfusion within 1 year;
* You have got the last vaccination of live attenuated vaccines within 2 weeks including measles, parotitis, or infantile paralysis, or got the last vaccination of live attenuated vaccines within 4 weeks including Rubella Vaccine, Rabies Vaccine for Human Use, Japanese Encephalitis Live Vaccine;
* You have accepted last immunization of Rabies Vaccine for Human Use after being bitten by an animal within 1 year;
* You have received the last vaccination of antitoxin or immune serum injection within 4 weeks, or got the last vaccination of hepatitis B human immunoglobulin within 1 year;
* You have been in a clinical trial within 6 months;
* You have clinical trial records within 3 months for the donation of WBC, plasma and platelet;
* You are evaluated by Investigator s as an unsuitable participant for this research.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYSKY-2022-115-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.